Reardon Andrew

CLO & SecretaryLIGAND PHARMACEUTICALS INC (LGND) · full profile →Form 4 · filed Jul 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.6M
Net Open-Market Flow
-$1.6M
Transactions
11
10 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 1, 2026Sell(S)600$317.15$190K42K
Jul 1, 2026Option exercise(M)5K$52.27$261K47K
Jul 1, 2026Sell(S)396$308.99$122K46K
Jul 1, 2026Sell(S)104$310.20$32K46K
Jul 1, 2026Sell(S)1K$311.72$349K45K
Jul 1, 2026Sell(S)1K$312.28$338K44K
Jul 1, 2026Sell(S)700$313.46$219K43K
Jul 1, 2026Sell(S)100$314.58$31K43K
Jul 1, 2026Sell(S)900$315.78$284K42K
Jun 30, 2026Other(J)132$160.71$21K42K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 1, 2026Option exercise(M)5K$034K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
J
Other acquisition / disposition

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002001011-26-000108) within minutes of acceptance. Every field above traces to the original document. Verify it directly: